Natera, Inc. reported $2.71B of revenue over the trailing twelve months, +38% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $2.71B (to Q2 2026). Net income: −$192M, trailing twelve months to Q2 2026. Free cash flow: $84M, trailing twelve months to Q2 2026. Operating margin: −11%, trailing twelve months to Q2 2026.

NTRANatera, Inc.

Healthcare

$400.63+121% 1Y

$400.63

$160.2152 weeks$425.55

NTRA as reported

Natera, Inc. reported $2.71B of revenue over the trailing twelve months, +38% on the year before. 10 reported series are charted on this page, each one as filed.

$2.71B

Revenue, trailing twelve months · to Q2 2026 · +38% against the twelve months before

Net income: −$192M
Net income · −24% year on year · trailing twelve months to Q2 2026
Free cash flow: $84M
Free cash flow · −19% year on year · trailing twelve months to Q2 2026
Operating margin: −11%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for NTRA, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$2.71B	+38%	Q2 2026
Net income	−$192M	−24%	Q2 2026
EPS	−$1.35	−29%	Q2 2026
Gross margin	49%	n/a	Q2 2020 · 24 quarters behind
Operating margin	−11%	n/a	Q2 2026
Net margin	−7.2%	n/a	Q2 2026
ROE	−15%	n/a	Q2 2026
ROA	−10%	n/a	Q2 2026
ROIC	−48%	n/a	Q2 2026
Free cash flow	$84M	−19%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.